Confirmation
Open All
Enoxaparin
Enoxaparin
Classification
Anticoagulant agent
Indications
ACP as part of CHAMP pathway
CCP
Adjunctive therapy to support thrombolysis in ST elevation myocardial infarction
Contraindications
- Known hypersensitivity to enoxaparin, heparin, pork products, or any other component of the formulation
- History of immune mediated heparin-induced thrombocytopenia in the past 100 days
- Major blood clotting disorders
- Active gastric or duodenal ulcer
- Hemorrhagic cerebrovascular accident
- Diabetic or hemorrhagic retinopathy
Adult dosages
ACP as part of CHAMP pathway
CCP
- Immediately prior to administration of tenecteplase: 30 mg IV bolus
- Do not administer IV enoxaparin to patients > 75 years of age
- Following administration of tenecteplase: 1 mg/kg SC
- For patients > 75 years of age: 0.75 mg/kg SC
Pediatric Considerations And Dosing
Not authorized for use in pediatrics
Mechanism Of Action
Enhances the inhibition rate of clotting proteases by antithrombin III.
Pharmacokinetics
Onset of action: 3-5 hours
Duration: ~12 hours
Half-life: 4.5-7 hours
Excretion: Urine
Adverse Effects
As an anticoagulant, enoxaparin may significantly increase the risk of bleeding and potentially fatal major hemorrhage.
Overdose
Considered unlikely. Protamine may be considered for use in overdose situations.
Warning And Precautions
Monitor patients closely for signs and symptoms of bleeding. Enoxaparin may precipitate the development of hyperkalemia in patients with additional risk factors for hyperkalemia.
Use with caution in elderly patients -- follow weight- and age-based dosing regimen.
Do not administer enoxaparin intramuscularly. May not be used interchangeably (unit for unit) with heparin or other low-molecular weight heparins.
Drug Interactions
May enhance anticoagulant effects of other medications.
Classification
Anticoagulant agent
Indications
ACP as part of CHAMP pathway
CCP
Adjunctive therapy to support thrombolysis in ST elevation myocardial infarction
Contraindications
- Known hypersensitivity to enoxaparin, heparin, pork products, or any other component of the formulation
- History of immune mediated heparin-induced thrombocytopenia in the past 100 days
- Major blood clotting disorders
- Active gastric or duodenal ulcer
- Hemorrhagic cerebrovascular accident
- Diabetic or hemorrhagic retinopathy
Adult dosages
ACP as part of CHAMP pathway
CCP
- Immediately prior to administration of tenecteplase: 30 mg IV bolus
- Do not administer IV enoxaparin to patients > 75 years of age
- Following administration of tenecteplase: 1 mg/kg SC
- For patients > 75 years of age: 0.75 mg/kg SC
Pediatric Considerations And Dosing
Not authorized for use in pediatrics
Mechanism Of Action
Enhances the inhibition rate of clotting proteases by antithrombin III.
Pharmacokinetics
Onset of action: 3-5 hours
Duration: ~12 hours
Half-life: 4.5-7 hours
Excretion: Urine
Adverse Effects
As an anticoagulant, enoxaparin may significantly increase the risk of bleeding and potentially fatal major hemorrhage.
Overdose
Considered unlikely. Protamine may be considered for use in overdose situations.
Warning And Precautions
Monitor patients closely for signs and symptoms of bleeding. Enoxaparin may precipitate the development of hyperkalemia in patients with additional risk factors for hyperkalemia.
Use with caution in elderly patients -- follow weight- and age-based dosing regimen.
Do not administer enoxaparin intramuscularly. May not be used interchangeably (unit for unit) with heparin or other low-molecular weight heparins.
Drug Interactions
May enhance anticoagulant effects of other medications.